• Active, not recruiting

NCT03318861: Phase 1: Study to Evaluate the Safety and Efficacy of KITE-585 in RRMM Multiple Myeloma

NCT03318861: Phase 1: Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma

kite585

NCT03318861: Phase 1: Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma


The primary objective of the study is to evaluate the safety and tolerability of KITE-585, an autologous engineered chimeric antigen receptor (CAR) T-cell product targeting a protein commonly found on myeloma cells called B-cell maturation antigen (BCMA), as measured by the incidence of dose-limiting toxicities (DLTs). Participants will be given a 3 day course of conditioning chemotherapy followed by a single infusion of KITE-585.


Sponsor

Gilead Sciences ( Kite, A Gilead Company )

 

ClinicalTrials.gov Identifier: NCT04892446

Official Title: A Phase 1 Multicenter Study of KITE-585, an Autologous Anti-BCMA CAR T-Cell Therapy, in Subjects With Relapsed/Refractory Multiple Myeloma

First Posted : October 24, 2017

Click here for details on ClinicalTrials.gov

 

KITE-585

Autologous Anti-BCMA CAR-transduced T-cells KITE-585 (Code C155883)

Autologous Anti-BCMA CAR-transduced T-cells KITE-585

Autologous Genetically Modified Anti-BCMA CAR-T Cells KITE-585

Autologous Genetically-modified Anti-BCMA CAR-transduced T-cells KITE-585

Autologous T-cells KITE-585

KITE 585

KITE-585

KITE585

 

Genetic: KITE-585

Drug: Cyclophosphamide

Drug: Fludarabine

 

Am J Cancer Res; 2021 Jun 15

A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma

Click here for details

 

Location

United States, California

United States, Florida

United States, Georgia

United States, Illinois

United States, Massachusetts

United States, Minnesota

United States, New York

United States, Tennessee

United States, Texas




Posts Archive